Thromb Haemost 1985; 53(02): 228-234
DOI: 10.1055/s-0038-1661281
Original Article
Schattauer GmbH Stuttgart

A Role for Pericellular Proteoglycan in the Binding of Thrombin or Antithrombin III by the Blood Vessel Endothelium? – The Effects of Proteoglycan-Degrading Enzymes and Glycosaminoglycan-Binding Proteins on 125I-Thrombin Binding by the Rabbit Thoracic Aorta In Vitro

Mark W C Hatton
The Department of Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
,
Sue L Moar
The Department of Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 16 October 1984

Accepted 15 January 1985

Publication Date:
18 July 2018 (online)

Summary

Rabbit thoracic aorta segments were treated with either proteoglycan-degrading enzymes or with glycosaminoglycan- binding proteins to examine the nature of the endothelial and subendothelial binding sites of 125I-thrombin. Treatment (5-30 min) with enzymes (heparitinase, chondroitinases AC or ABC) caused a decrease in 125I-thrombin binding by the endothelium (30-70%) and by the subendothelial (intima-media) layer (20-50%); a low- specificity protease destroyed endothelial binding almost entirely and reduced binding to the subendothelium by approximately 60% over a similar period. Of the glycosaminoglycan-binding proteins, pretreatment of the aorta wall with protamine caused a 30% decrease in thrombin binding to the endothelium whereas lipoprotein lipase (present during 125I-thrombin uptake) decreased binding by up to 40%. Pretreatment with antithrombin III did not significantly affect binding of either 125I-thrombin or 125I-FPR-inactivated thrombin. In contrast to thrombin, 125I- antithrombin III was not readily uptaken by the aorta segments. These observations indicate that, whereas the minimal binding by 125I-antithrombin III probably does not involve endothelial proteoglycan, a strong case can be made for endothelial and subendothelial proteoglycan binding sites for thrombin..

 
  • References

  • 1 Kirk JE. Anticoagulant activity of human arterial mucopolysaccharides. Nature 1959; 184: 369-370
  • 2 Gore I, Larkey BJ. Functional activity of aortic mucopolysaccharides. J Lab Clin Med 1960; 56: 839-846
  • 3 Teien A, Abildgard U, Hook M. The anticoagulant effect of heparan sulphate and dermatan sulphate. Thromb Res 1976; 8: 859-867
  • 4 Hatton MW C, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta. Thromb Res 1978; 13: 655-670
  • 5 Markwardt F, Walsman R. Untersuchungen über den Mechanismus der Antithrombinwirkung des Heparins. Hoppe-Seylers Z Physiol Chem 1959; 317: 64-77
  • 6 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
  • 7 Buonassisi V. Sulfated mucopolysaccharides synthesis and secretion in endothelial cell cultures. Exp Cell Res 1973; 76: 363-368
  • 8 Buonassisi V, Root M. Enzymatic degradation of heparin-related mucopolysaccharides from the surface of endothelial cell cultures. Biochim Biophys Acta 1975; 385: 1-10
  • 9 Simionescu M, Simionescu N, Silbert JE, Palade GE. Differentiated microdomains on the luminal surface of the capillary endothelium II. Partial characterization of their anionic sites. J Cell Biol 1981; 90: 614-621
  • 10 Marcum JA, Fritze L, Galli SJ, Karp G, Rosenberg RD. Microvascular heparin-like species with anticoagulant activity. Am J Physiol 1983; 245: H725-H733
  • 11 Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin III complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-350
  • 12 Lollar P, Macintosh SC, Owen WG. Reaction of antithrombin III with thrombin bound to the vascular endothelium. J Biol Chem 1984; 259: 4335-4338
  • 13 Olivecrona T, Egelrud T, Iverius PH, Lindahl U. Evidence for an ionic binding of lipoprotein lipase to heparin. Biochem Biophys Res Commun 1971; 43: 524-529
  • 14 Scott JE. Affinity, competition and specific interactions in the biochemistry and histochemistry of polyelectrolytes. Biochem Soc Trans 1973; 1: 787-806
  • 15 Hatton MW C, Dejana E, Cazenave J-P, Regoeczi E, Mustard JF. Heparin inhibits thrombin binding to the rabbit thoracic aorta endothelium. J Lab Clin Med 1980; 96: 861-870
  • 16 Hatton MW C, Moar S. Uptake and catabolism of 125I-thrombin by the rabbit thoracic aorta in vitro: Permeability of the endothelium, intima-media and adventitial layers. Thromb Haemostas 1984; 52: 105-111
  • 17 Lundblad RL, Uhteg LC, Vogel CN, Kingdon HS, Mann KG. Preparation and partial characterization of two forms of bovine thrombin. Biochem Biophys Res Commun 1975; 66: 482-489
  • 18 Deutsch DG, Mertz ET. Plasminogen: purification from plasma by affinity chromatography. Science 1970; 170: 1095-1096
  • 19 Hatton MW C, Regoeczi E. Some observations on the affinity chromatography of rabbit plasminogen. Biochim Biophys Acta 1974; 359: 55-65
  • 20 Claeys H, Molla A, Verstraete M. Conversion of NH2-terminal glutamic acid to NH2-terminal lysine human plasminogen by plasmin. Thromb Res 1973; 3: 515-523
  • 21 Hatton MW C, Regoeczi E. The inactivation of thrombin and plasmin by antithrombin III in the presence of Sepharose-heparin. Thromb Res 1977; 10: 645-660
  • 22 Bengtsson G, Olivecrona T. Interaction of lipoprotein lipase with heparin-Sepharose. Evaluation of conditions for affinity binding Biochem J 1977; 167: 109-119
  • 23 Egelrud T, Olivecrona T. Purified bovine milk lipoprotein lipase: Activity against lipid substrates in the absence of exogenous serum factors. Biochim Biophys Acta 1973; 306: 115-127
  • 24 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
  • 25 Miller-Andersson M, Borg H, Andersson L-O. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-452
  • 26 Pugatch EM J, Saunders AM. A new technique for making Hautchen preparations of unfixed aortic endothelium. J Atheroscler Res 1968; 8: 735-738
  • 27 Andrews P, Milsom DW, Ford WL. Migration of lymphocytes across specialized vascular endothelium V. Production of a sulphated macromolecule by high endothelial cells in lymph nodes. J Cell Sci 1982; 57: 277-292
  • 28 Olivecrona T, Bengtsson G, Marklund S-E, Lindahl U, Höök M. Heparin-lipoprotein lipase interactions. Fed Proc 1977; 36: 60-65
  • 29 Shimada K, Gill PJ, Silbert JE, Douglas WH J, Fanburg BL. Involvement of cell surface heparan sulfate in the binding of lipoprotein lipase to cultured bovine endothelial cells. J Clin Invest 1981; 68: 995-1002
  • 30 Cheng C-F, Oosta GM, Bensadoun A, Rosenberg RD. Binding of lipoprotein lipase to endothelial cells in culture. J Biol Chem 1981; 256: 12893-12898
  • 31 Dryjski M, Larsson R, Olsson P, Swedenborg J. Effect of glycosaminoglycans and antithrombin III on uptake and inhibition of thrombin by the vascular wall. Thromb Res 1983; 32: 355-363
  • 32 Ong EB, Johnson AJ. Protamine, a substrate for thrombolytic agents and enzymes of similar specificity. Anal Biochem 1976; 75: 568-582
  • 33 Hatton MW C, Rollason G, Sefton MV. Fate of thrombin and thrombin-antithrombin III complex adsorbed to a heparinized biomaterial: Analysis of the enzyme-inhibitor complexes displaced by plasma. Thromb Haemostas 1983; 50: 873-877
  • 34 Blackburn MN, Smith RL, Carson J, Sibley CC. The heparin binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence. J Biol Chem 1984; 259: 939-941
  • 35 Awbrey BJ, Hoak JC, Owen WG. Binding of human thrombin to cultured human endothelial cells. J Biol Chem 1979; 254: 4092-4095
  • 36 Busch C, Owen WG. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. J Clin Invest 1982; 69: 726-729
  • 37 Savion N, Farzame N. Binding, uptake and degradation of antithrombin III-protease complexes by cultured corneal endothelial cells. Exp Cell Res 1984; 153: 50-60